EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische Studie

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

Stephen J Nicholls, Imre Pavo, Deepak L Bhatt, John B Buse, Stefano Del Prato, Steven E Kahn, A Michael Lincoff, Darren K McGuire, Debra Miller, Michael A Nauck iD, Hiroshi Nishiyama, Steven E Nissen iD und 16 weitere

New England Journal of Medicine · 18.12.2025 · 393 (24) · 2409-2420

DOI: 10.1056/nejmoa2505928 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 18.12.2025. Verfasst von Stephen J Nicholls und 27 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Heart Institute, Monash University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit wurde bisher 261-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Immunoglobulin Fc FragmentsRecombinant Fusion ProteinsTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAgedFemaleHumansMaleMiddle AgedBlood GlucoseDouble-Blind MethodGlucagon-Like PeptidesGlycated HemoglobinInjections, SubcutaneousIntention to Treat AnalysisTreatment Outcome

Substanzen

Blood GlucosedulaglutideGlucagon-Like PeptidesGlycated HemoglobinImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
  • Eli Lilly, Indianapolis.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York.
  • University of North Carolina, Chapel Hill.
  • Interdisciplinary Research Center "Health Science," Sant'Anna School of Advanced Studies, Pisa, Italy.
  • Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle.

ORCID-Profile: Michael A Nauck, Steven E Nissen, Naveed Sattar, Linong Ji

Förderung

  • Eli Lilly and Company

Zitieren

APA

Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., Nishiyama, H., Nissen, S. E., Sattar, N., Weerakkody, G., Wiese, R. J., Zinman, B., Zoungas, S., Basile, J., Davies, M. J., …, & SURPASS-CVOT Investigators (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 393(24), 2409-2420. https://doi.org/10.1056/nejmoa2505928

Vancouver

Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025;393(24):2409-2420. doi:10.1056/nejmoa2505928

BibTeX
@article{Nicholls2025,
  author = {Nicholls, Stephen J and Pavo, Imre and Bhatt, Deepak L and Buse, John B and Del Prato, Stefano and Kahn, Steven E and Lincoff, A Michael and McGuire, Darren K and Miller, Debra and Nauck, Michael A and Nishiyama, Hiroshi and Nissen, Steven E and Sattar, Naveed and Weerakkody, Govinda and Wiese, Russell J and Zinman, Bernard and Zoungas, Sophia and Basile, Jan and Davies, Melanie J and Giorgino, Francesco and Kellerer, Monika and Ji, Linong and Varkonyi, Tamas and Menon, Venu and Broder, Jonathan C and Herschtal, Alan and D'Alessio, David and SURPASS-CVOT Investigators, SURPASS-CVOT Investigators},
  title = {Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {24},
  pages = {2409--2420},
  doi = {10.1056/nejmoa2505928}
}
Kostenlos starten →